Your AI-Trained Oncology Knowledge Connection!
A pooled analysis of 3 randomized controlled trials found that pembrolizumab plus chemotherapy demonstrated response and survival improvements with a manageable safety in comparison with chemotherapy alone in PD-L1‒negative advanced non-small cell lung cancer.
This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
The study found that high levels of sustained factor VIII activity, which followed a normalization period after BIVV001 administration, might offer better protection against all types of bleeding and a longer interval between administration of the product in this patient population.
A study found that delaying radiation therapy while remaining on hormone therapy for patients with unfavorable intermediate-risk or high-risk localized prostate cancer to avoid potential exposure to COVID-19 did not negatively impact overall survival.
Mesoblast Limited announced that the FDA issued a complete response letter regarding its biologics license application for remestemcel-L to treat pediatric patients with SR-aGVHD after the ODAC voted 9:1 in favor of the available efficacy and data.
Researchers suggested that the current situation be used as an opportunity to re-evaluate standard practices for clinical trials in order to make them more accessible and less stressful for potential patients and thus allow for broader participation.
The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.
A study found that radiation therapy to treat childhood abdominal and pelvic cancers potentially caused body composition abnormalities and worse cardiometabolic health for adult survivors compared to the general public.
The FDA granted fast track designation to the novel “switchable” CAR-T cell therapy known as CLBR001 + SWI019 for the treatment of B-cell malignancies.
The survey revealed that approximately two-thirds of Americans reported that their scheduled cancer screenings have been delayed or skipped due to the COVID-19 pandemic.
The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung cancer with high PD-L1 expression, regardless of histologic type, in May.
The findings from this study are intended to inform the Curriculum for Oncologists on LGBTQ+ populations to Optimize Relevance and Skills (COLORS) Training Program.
According to researchers, these findings suggest “that as long as a person is not smoking at the time of chemotherapy and surgery, they might do better.”
CancerNetwork examines a review article in the September issue of the journal ONCOLOGY discussing precision medicine and molecular profiling for patients with metastatic colorectal cancer.
Among men with advanced prostate cancer, relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.
xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The ATR inhibitor BAY 1895344 appeared promising in patients with a range of advanced, heavily pre-treated cancers in a dose-escalation portion of a phase 1 clinical trial.
The FDA issued the final guidance in order to help improve the information available to patients and health care providers about the risks of breast implants.
TLX591-CDx (illumet) is a radiopharmaceutical targeting prostate-specific membrane antigen intended for the imaging of prostate cancer using positron emission tomography.
These study findings suggested that topical minoxidil and procedural interventions may aid in the treatment of persistent radiation-induced alopecia among patients with primary central nervous system tumors or head and neck sarcomas.
This study found that among clinical trials in which patients with non-small cell lung cancer were treated with atezolizumab, multiorgan immune-related adverse events were reported in 5.4%.
According to researchers, this “group represents more than 20% of children and young adults with ALL, and an increase in attention to adherence, supportive care, and logistics for patients living [more than 50] miles from their treatment center is warranted.”
The study is evaluating the efficacy and safety of sintilimab injection in combination with bevacizumab biosimilar injection compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma.
A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.
Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.
The phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial indicated that the addition of atezolizumab to bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.
According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”
Sotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.
Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.
